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Background: Diagnosing asthma cannot be always easy. It is important to consider the
validity of the diagnostic tests, and/or how much more commonly they are positive in
patients with asthma compared to healthy subjects and, particularly, to patients with
asthma-like symptoms.
Objective: To evaluate the validity of diagnostic tests for asthma, in terms of sensitivity,
speciﬁcity, positive and negative predictive values, in patients with bronchial asthma
compared to patients affected by gastro-oesophageal reﬂux disease (GERD) with asthma-
like symptoms, and healthy control subjects without asthma and gastro-oesophageal reﬂux
(GER).
Design: Single-center, cross-sectional, observational study.
Patients: We studied 60 patients with mild asthma, 30 patients with GERD and asthma-
like symptoms and 25 healthy control subjects.
Measurements: We measured provocative concentration of methacholine causing a 20%
fall in the forced expiratory volume in 1 s (MCh PC20/FEV1), the amplitude percent mean ofElsevier Ltd. All rights reserved.
eal reﬂux; GERD, gastro-oesophageal reﬂux disease; FEV1, forced expiratory volume in 1 s; FVC, forced
Ch PC20/FEV1, provocative concentration of MCh causing a 20% fall in FEV1; A%M of PEF, amplitude
; ECP, eosinophil cationic protein
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G. Di Lorenzo et al.1456peak expiratory ﬂow (A%M of PEF), derived from twice-daily readings for 42 weeks, the
FEV1/forced vital capacity (FEV1/FVC) ratio, the eosinophil count in blood and in induced
sputum and the serum eosinophil cationic protein (ECP) levels.
Results: FEV1/FVC ratio, A%M of PEF, blood eosinophils counts and serum ECP levels were
less sensitive and speciﬁc when the reference population was composed of patients with
asthma-like symptoms by GER. While, MCh PC20/FEV1 and induced sputum eosinophils
count were the most sensitive (both 90%) and speciﬁc (89% and 92%, respectively) tests.
Conclusion: Our ﬁndings demonstrate that MCh PC20/FEV1 and the induced sputum
eosinophil count are the most useful objective tests in patients with mild asthma. All
patients with asthma presented both an MCh PC20/FEV1o1500 mg and eosinophils count in
the induced sputum 41%.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Gastro-oesophageal reﬂux disease (GERD) is a condition with
relatively high incidence and it may be associated with
chronic/recurrent respiratory symptoms.1,2 GERD can in-
duce asthma-like symptoms, such as coughing and breath-
lessness, through two major mechanisms: inhalation of
gastric content in the airways and vagal reﬂexes precipi-
tated by acid in the lower oesophageal portion and/or in the
larynx.3 These reﬂexes, through the release of tachykinins
and other neurotransmitters by nociceptive airways afferent
nerves, mediate not only cough, bronchospasm, mucus
secretion and vasodilation, but also a ‘‘neurogenic inﬂam-
mation’’ characterized by the recruitment of polymorpho-
nuclear leukocytes.4,5
Differential diagnosis between bronchial asthma and
asthma-like symptoms induced by GERD is not always easy,
and it is based on the use of some investigative tests. The
extent to which of these tests alter the probability of a
diagnosis of bronchial asthma depends on the validity of the
test, and/or how much more commonly the test results are
positive in patients with bronchial asthma compared to
healthy subjects and patients with conditions that are
commonly confused with asthma, such as GERD with asthma-
like symptoms.6 However, many patients with bronchial
asthma present gastro-oesophageal reﬂux (GER).
Few studies have compared the sensitivity and speciﬁcity
of different tests in patients with bronchial asthma and none
have done so using a reference population of patients
affected by GERD with asthma-like symptoms.
Bronchial asthma can often be diagnosed on the basis of
symptoms. However, measurements of lung function, and,
particularly, of an abnormal, short-term, variable airﬂow
obstruction, greatly enhanced diagnostic conﬁdence. Spon-
taneous variable airﬂow obstruction can be assessed using a
twice-daily peak expiratory ﬂow (PEF) monitoring at home.
Otherwise, treatment-induced variable airﬂow obstruction
can be assessed in the laboratory by measuring the broncho-
constrictor response to short-acting airway smooth muscle
spasmogens, such as methacholine (MCh).7
We compared the validity of provocative concentration of
methacholine causing a 20% fall in the forced expiratory
volume in 1 s (MCh PC20/FEV1) in terms of sensitivity and
speciﬁcity, positive and negative predictive values, together
with FEV1/forced vital capacity (FVC) ratio, blood and
induced sputum eosinophil counts, and serum eosinophil
cationic protein (ECP) levels in 60 patients with mildbronchial asthma, 30 patients affected by GERD with
asthma-like symptoms, and 25 healthy subjects, without
asthma and GERD or GER.Material and methods
Patients
Patients and healthy subjects were recruited from the
patients attending the Units of Allergology and of Gastro-
enterology of the Dipartimento di Medicina Clinica e delle
Patologie Emergenti of the University of Palermo (Italy) and
from the Units staff. The study was carried out during the
period between January 2002 and December 2003.
Our institutional policy and the ethical committee in our
institution do not require that an ethics committee
authorize the study. However, institutional policy requires
the patient’s written informed consent for us to perform the
tests; we obtained consent in every case.
Mild bronchial asthma was diagnosed in 60 asthmatic
patients. The subjects had consistent clinical features, were
symptomatic at the time of the evaluations, had basal FEV1
valuesX80% of predicted, and presented one or more of the
following conditions: a 15% increase in FEV1 10min after
receiving 200 mg of inhaled salbutamol. All patients had a
stable asthma, deﬁned as stable asthma symptoms and no
change in asthma medication during 2 weeks before study
entry. Furthermore, no respiratory tract infection was
reported within 3 months before study entry. None of the
asthmatic patients reported dysphagia, and/or epigastric
pain, heartburn and/or regurgitation, and/or water brash.
However, in 48% of these, the 24-h oesophageal pH study
demonstrated the presence of GER.
GERD with asthma-like symptoms was diagnosed in 30
patients. All patients had symptoms of GER (heartburn and/or
regurgitation at least twice a month, and/or water brash, and/
or dysphagia, and/or epigastric pain) and abnormal amounts of
acid reﬂux, documented by 24-h oesophageal pH study, and
deﬁned as total percent time pHo4 during the 24-h study
period exceeded 1.10% or upright acid exposure exceeded
1.70%, or supine acid exposure exceeded 0.60%.1 The asthma-
like symptoms (i.e. cough and/or breathless) did not deterio-
rate following the withdrawal of asthma therapy (oral
corticosteroid, and/or oral theophylline, and/or short-acting
b2-agonists). Both respiratory and gastric symptoms improved
with the treatment with proton pump inhibitors (PPI).
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history of scleroderma, oesophageal, gastric or pulmonary
surgery, or the presence of other pulmonary (i.e. chronic
bronchitis, or other forms of chronic lung disease), cardiac
or systemic disorders, that could interfere with interpreta-
tion of results or preclude completion of the study.
Twenty-ﬁve healthy control subjects had no symptoms
suggesting past or current bronchial asthma or asthma-like
symptoms by GERD. In these subjects, GERD and GER were
excluded to endoscopy and 24-h oesophageal pH study.
Design of study
This was a single-center, cross-sectional, observational
study. Patients and controls were evaluated at a ﬁrst
ambulatory visit and then after 14 days. On the ﬁrst day of
attendance, all patients and controls completed a detailed
demographic questionnaire assessing asthma and GER
symptoms and underwent clinical examination. Then,
spirometry, allergen skin prick tests, peripheral blood
eosinophil counts, and serum ECP levels were performed,
and the subjects were asked to record, on a diary, twice-
daily PEF values. On the second attendance, 14 days later, a
MCh inhalation test was performed, followed by sputum
induction after recovery from MCh test. All laboratory
measurements were performed by a blinded observer.
Patients with bronchial asthma continued to receive their
usual therapy throughout the investigation period, although
short-acting b2-agonists were withheld for 6 h before the
evaluation of airway responsiveness. Subjects with GERD
and asthma-like symptoms were studied at least 1 month
after stopping all asthma medication, but continued to
receive their therapy for GERD, with PPI.
Spirometry
Lung function measurements and MCh PC20/FEV1
FEV1 was measured with a Gould 2400 automated system
(Sensormedics BV, Bilthoven, Netherlans), taking into
account the highest of 3 successive measurements, provided
that the difference between measurements was within
100mL. FEV1, FVC, FEV1/FVC ratio, and PEF were deter-
mined.
Patients and control subjects measured their PEF at
home, twice daily, in the morning, on waking, and in the
evening, at bedtime, for 14 days, as the best of three blows,
using a mini-Wright peak ﬂowmeter (Clement Clarke Ltd;
London, UK), and were asked to register PEF measurements
on a diary, assigned at the ﬁrst visit, and collected at the
second visit.11
MCh challenge was performed according to the Chai’s
method.8–10 Increasing concentrations of MCh were adminis-
tered with a MEFAR nebulizer (Markos, Monza, Italy). After
taking baseline measurements of FEV1, subjects inhaled ﬁve
puffs of saline solution. The diluent value was considered as
the control, and, if the FEV1 variations were within 10% of
baseline, the patients were enrolled in the study. Subjects
then inhaled increasing concentrations of MCh, ranging from
16 to 5120 mg/mL, at 5-min intervals, until a 20% decrease
from the baseline FEV1 was recorded. The MCh PC20/FEV1
was determined by computer-assisted logarithmic interpo-lation of the log dose–response curve. If the patients did not
react, a censored value of 5120 mg was given.9,10Skin prick tests
Skin Prick Tests (Alk Abello`, Milan, Italy) for common
aeroallergens of West Sicily [trees (Olea europea and
Cupressus), grass pollens (Lolium perenne, Cynodon,
Phleum pratense), mugwort (Compositae), wall pellitory
(Parietaria judaica), house dust mite mites (Dermatopha-
goides pteronyssinus and farinae), moulds (Alternaria
alternata, Aspergillus, Cladosporium herbarum, Candida,
Penicillium), dog and cat dander, and Blatella germanica]
were performed on the volar aspect of the forearm after
anti-histamines had been withheld for at least 5 days.
Glicerine and histamine (10mg/mL) were used as negative
and positive controls, respectively. A positive response was
deﬁned as any wheal with a diameter 3mm greater than the
negative control, 15min after the application.12Laboratory analyses
Peripheral blood eosinophil counts
A venous blood sample was collected, and absolute
peripheral blood eosinophil counts were determined with
Technicon-H1 blood cell counter (Bayer Leverkusen, Ger-
many). The normal range is 0.10–0.40 103 cells/mL.12–15Sputum induction and processing
After baseline FEV1 and FVC measurements, salbutamol was
given by inhalation (200 mg by metered-dose inhaler), and
subjects inhaled hypertonic (4.5%) saline nebulized solution
for periods of progressively increasing length (1, 2, 4, 8, and
16min.). FEV1 was measured 1min after each inhalation.
Increasing concentrations were administered with a MEFAR
nebulizer (Markos, Monza, Italy). The collected sputum
samples were examined within 2 h. Selected portions of the
sputum sample originating from the lower respiratory tract
were chosen through examination with an inverted micro-
scope, were weighed, and then, processed using 1%
dithiothreitol (Sigma Chemicals, Poole, UK). Total cell count
and viability (Trypan blue exclusion method) were deter-
mined with a Burkers chamber hemocytometer. The cell
suspension was placed in a Shandon cytocentrifuge (Shandon
Southern Ltd., Runcorn, UK) and cytospin preparations were
made at 450 rpm for 6min. Cytospin slides were ﬁxed with
methanol, were stained with May-Grunwald-Giemsa for an
overall differential cell count of 500 nucleate nonsquamous
cells, and were examined, under oil immersion by light
microscopy, at magniﬁcation of 400 , by an observer
unaware of the clinical characteristics of the subjects. Only
samples with a cell viability 450% and o20% squamous cell
contamination were considered. The normal range for
eosinophil count was o1%.16,17Serum ECP
Serum ECP assay was determined by CAP system FEIA
(Pharmacia, Uppsala, Sweden) as previously described. The
normal range for the assay is o16 mg/mL.12–15
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The basal spirometric values, the peripheral blood eosino-
phil counts and the serum ECP levels were presented as
mean7SEM.
The MCh PC20/FEV1, and the induced sputum eosinophil
counts were log normally distributed, log-transformed, and
presented as geometric mean7SEM. For log transformation,
a value of 0.01% was assigned to a induced sputum
eosinophil count of 0%.
The maximum PEF amplitude percent mean (maximum
PEF A%M), expression of diurnal PEF variability, was derived
from the maximum within-day PEF variability observed
during the 14-days period after the ﬁrst and before the
second visit, measured as the difference between the
highest and the lowest daily PEF measurements, and was
expressed as a percentage of the mean PEF.
The comparison between the three groups were examined
using Kruskal–Wallis test. For statistical analyses, a value of
Po0.05 was considered statistically signiﬁcant.
Sensitivity and speciﬁcity (with 95% conﬁdence intervals),
positive and negative predictive values, accuracy and
likelihood ratios of positive and negative results were
calculated using SYSTAT 10 software package for Windows
(SPSS Inc, Chicago, IL). We consider for each analysis that
the prevalence of asthma was 52.1%.
Finally, we used the following formulas to determine
global sensitivity (Eq. (1)) global speciﬁcity (Eq. (2)) and
global predictive positive value (Eq. (3)) of two tests used in
succession (MCh and eosinophils-induced sputum).18
global specificity ¼ true positive to second test
patients with diagnosis of asthma
; (1)
global sensitivity
¼ true negative to first testþ true negative to second test
patients without diagnosis of asthma
;
ð2Þ
global predictive positive value ðPPVÞ
¼ true positive to second test
total positive to second test
. ð3ÞTable 1 Characteristics of the subjects.
Healthy control su
(N ¼ 25)
Age yr (range) 34.5 (19–55)
Men no. 12
Atopy (%) 6
Current smokers (%) 0
Inhaled steroid use (%) 0
Theophylline use (%) 0
Oral steroid use (%) 0
b2-short acting on demand (%) 0
Proton pump inhibitors (%) 0
Prokinetic agent (%) 0Results
Subjects details are shown in Table 1. All the groups were
sex- and age-matched. Atopy was demonstrated in 56% of
the patients with bronchial asthma, in 2% of the patients
with GERD and asthma-like symptoms, and in 6% of healthy
control subjects.
Patients with GERD and asthma-like symptoms had
received an asthma treatment, many of them were treated
with regular oral theophylline and/or inhaled b2 short-acting
and/or oral corticosteroids (i.e. prednisone) therapy, but
without clinically relevant results.
In Table 2 we reported the mean7SEM of FEV1/FVC ratio,
maximum PEF A%M, peripheral blood eosinophil counts, and
serum ECP levels and the geometric mean7SEM of MCh
PC20/FEV1 and induced sputum eosinophil counts. Signiﬁcant
differences were found between asthmatics patients and
healthy control subjects (Po0.001) and between asthmatics
patients and patients with GERD and asthma-like symptoms
(Po0.001). No differences were found between healthy
control subjects and patients with GERD and asthma-like
symptoms.
Normal range and the distribution of individual values in
the three groups considered for FEV1/FVC ratio, maximum
PEF A%M, MCh PC20/FEV1, induced sputum and blood
eosinophil counts, and serum ECP levels are shown in Fig.
1(a)–(f).
The sensitivity, speciﬁcity, positive and negative predic-
tive values and likelihood ratios of the test results are shown
in Table 3.
The MCh PC20/FEV1 and induced sputum eosinophil counts
were the most sensitive (both 90%) and speciﬁc (89% and
92%, respectively) tests.
The maximum PEF A%M was less valid than the identiﬁca-
tion of an obstructive spirogram, and the sensitivity of this
parameter was low (20%) whereas the speciﬁcity was higher
(83%). Blood eosinophils counts and serum ECP levels
presented a high speciﬁcity (90% and 92%, respectively)
but a low sensitivity (66% and 70%, respectively).
Finally, we calculated the global sensitivity, the global
speciﬁcity, and the global PPV evaluating the presence of
eosinophils in induced sputum only in subjects with MCh
PC20/FEV141500 mg/mL. The global sensitivity was 80%, the















Table 2 Mean or geometric mean7SEM of the evaluated parameters.
Healthy control subjects Asthma patients GER patients
FEV1/FVC ratio
 81.371.3 76.670.4 79.970.5
Maximum PEF A%M 9.171.2 14.670.6 10.571.1
MCh PC20/FEV1
y 1897.6796.1 304.7768.1 1957.87123.2
Blood eosinophils 0.2070.02 0.4670.005 0.2070.016
Serum ECP levels 4.670.8 17.470.8 5.670.8
Induced sputum eosinophilsy 0.1370.09 5.3770.38 0.1470.08
Mean7SEM.
yGeometric mean7SEM.
Figure 1 (a–f) Individual values for FEV1/FVC ratio, PEF A%M, MCh PC20/FEV1, blood eosinophil counts, serum ECP levels, and
induced sputum eosinophil counts, in each patient category.
Diagnostic tests in mild asthmatics and patients with gastro-oesophageal reﬂux and asthma-like symptoms 1459None of the patients with bronchial asthma presented the
combination of MCh PC20/FEV141500 mg/mL and presence
of eosinophils in induced sputum, and none of the patients
with GERD and asthma-like symptoms presented abnormal
results for both and simultaneously of these parameters.Discussion
This is the ﬁrst study comparing the validity of different
tests for the diagnosis of bronchial asthma with reference to
a population that has a condition that is often confused with
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Table 3 Measurement categories of various tests.



















7 83 (71.4–91.7) 67 (53.2–79.3) 73 78 2.5 0.2
PEF A%M o20%7 20 (10.7–32.3) 83 (71.2–92.2) 57 48 1.2 0.9
Mch PC20/FEV1 41500 mg/ml
7,9 90 (79.4–96.2) 89 (77.7–95.8) 90 89 8.2 0.1
Blood
eosinophils
o0.45 103/mL10 66 (53.3–78.3) 90 (80.0–96.9) 88 71 7.3 0.3




o116 90 (79.4–96.2) 92 (82.4–97.9) 93 89 12.3 0.1
G. Di Lorenzo et al.1460bronchial asthma (i.e. GERD with asthma-like symptoms).
The results of this study indicate that, in adults with
diagnosis of mild bronchial asthma, and normal or near
normal basal spirometric values, MCh broncho-constrictor
response (i.e. MCh PC20/FEV1) and the count of eosinophils
in induced sputum are the most valid tests, in terms of both
sensitivity and speciﬁcity, and, by implication, the most
clinically useful tests for discriminating these patients from
subjects with asthma-like symptoms by GERD. Making the
distinction between bronchial asthma and asthma-like
symptoms by GERD is an important problem in medical
practice.7 Patients reporting asthma-like symptoms by
GERD are likely to be representative of a wider population
with a condition that is commonly confused with bronchial
asthma.1–5
GERD is particularly common in infants, but the problem
may persist in many older children and in adults.19
Mechanism of gastro-oesophageal acid-induced bronchocon-
striction have been examined on a pathophysiologic basis,
and include microaspiration, vagally mediated reﬂex, and
enhanced bronchial reactivity. However, other mechanisms
also may play a role in producing respiratory symptoms in
response to gastro-oesophageal acid. For example, neuro-
genic inﬂammation, with tachykinin/substance P release,
airway oedema and recruitment of polymorphonuclear
leucocyte, resulting from acid stimulation, have been
demonstrated.
An ambulatory 24-h pH study needs to be performed to
conﬁrm the diagnosis of GERD, both in children and in
adults, evaluating total percent time pHo4 during the 24-h
study period, upright acid exposure and supine acid
exposure.1,20,21
Interestingly, the prevalence of GER, in people with
bronchial asthma, is higher than in control populations.
Patients with bronchial asthma may be prone to develop
GER because of an increased pressure gradient between
the abdominal cavity and the thorax, over-riding the
lower oesophageal sphincter pressure barrier, alterations
in crural diaphragm function, autonomic dysregulation, anti-
asthmatic drugs use, and a high prevalence of hiatal
hernia.22 In our study 48% (29/60) of asthmatic patients
presented GER evaluated with 24-h oesophageal pH study.
However, we have not found any signiﬁcant differencebetween asthmatic patients with GER and without GER, as
regards to the symptoms and the parameters studied (data
not shown).
In our study, the combination of the absence of bronchial
hyper-responsiveness to MCh and of the absence of
eosinophils in induced sputum exclude the diagnosis of
bronchial asthma.7 In fact, our data demonstrated the
presence of eosinophils, both in peripheral blood and in
induced sputum of the patients with bronchial asthma
comparing with patients with GERD and asthma-like symp-
toms, can be important for the choice of the therapy. The
lung inﬂammation in patients affected by GERD is pre-
dominantly a neutrophil-driven process, while that in
bronchial asthma depends mostly on eosinophils and
lymphocytes, although more severe forms of asthma tend
to be associated with neutrophils as well.5,23 In particular, in
patients with GERD and asthma-like symptoms, the presence
of macrophages and neutrophils, activated, in the lung, by
the phagocitosis of inhaled gastric organic fat or proteins,
led to an increased production of IL-8, having an active
pathogenetic role in the recruitment and activation of
neutrophils in the airways. Whereas, in severe asthma,
epithelial damage has the potential to contribute to
demonstrated neutrophilic inﬂammation through enhanced
production of IL-8 via epidermal growth factor receptor-
dependent mechanisms.5,23
So, we demonstrated that the presence of eosinophils in
induced sputum can be a valid marker of bronchial asthma
and it is more sensitive and speciﬁc than blood eosinophil
counts. Similar ﬁndings have been reported by other
authors.5,24,25 Interestingly, the combination of the pre-
sence of MCh airway hyperresponsiveness and of eosinophilia
in induced sputum presents a high speciﬁcity in patients
with bronchial asthma.
In conclusion, we have demonstrated that the MCh
PC20/FEV1 and the induced sputum eosinophil counts
are the most sensitive and speciﬁc markers of mild bron-
chial asthma, able to discriminate asthma from asthma-
like symptoms by GERD. Our ﬁndings suggest that, in
patients with GERD and asthma-like symptoms, both MCh
PC20/FEV1 and induced sputum eosinophil counts are
necessary to support or exclude the diagnosis of bronchial
asthma.
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